A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy

A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy

Abstract Background The aggressive form of Mantle cell non-hodgkin B cell lymphoma (MCL) has a dismal prognosis. Dual targeting BTK and BCL2 with ibrutinib and venetoclax has improved outcomes in MCL patients who were predicted not to respond to conventional therapy, but it is unlikely to be curativ...

Full description

Bibliographic Details
Main Authors: Tongjuan Li, Yuanyuan Zhang, Dan Peng, Xia Mao, Xiaoxi Zhou, Jianfeng Zhou
Format: Article
Language:English
Published: BMJ Publishing Group 2019-02-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Haplo-identical CAR T cell therapy
Mantel cell lymphoma
Online Access:http://link.springer.com/article/10.1186/s40425-019-0529-9

Internet

http://link.springer.com/article/10.1186/s40425-019-0529-9

Similar Items